Purpose {#S0001}
=======

Locally advanced cervical cancer is optimally treated by concurrent chemo-radiotherapy \[[@CIT0001]--[@CIT0003]\]. Radiotherapy includes external beam radiotherapy (EBRT), followed by a brachytherapy boost. Several studies have shown that the outcome of patients treated for bulky and advanced stage disease is directly correlated with the combined dose of radiation delivered by EBRT and brachytherapy \[[@CIT0004]--[@CIT0006]\]. Intracavitary brachytherapy involves insertion of a uterine tandem into the cervix and uterus. Sub-optimal insertion of uterine tandem can perforate the uterus and can result in increased dose to nearby organs-at-risk (OARs). A perforation rate of 8% has been reported in applicators insertions, even if the operator is confident of placement \[[@CIT0007], [@CIT0008]\]. Uterine perforation is a potential complication of uterine tandem insertion, as a result of the tandem being inserted in a false passage outside the uterine canal. If perforation remains undetected and radiation delivered, this can significantly affect the treatment outcome \[[@CIT0009]--[@CIT0011]\].

The purpose of this study was to retrospectively assess the incidence of sub-serosal and uterine perforation in intracavitary high-dose-rate (HDR) brachytherapy for cervical cancer, and to evaluate its effects on computed tomography (CT)-based treatment planning dosimetry.

Material and methods {#S0002}
====================

Cervical cancer patients treated with HDR brachytherapy from February 2006 to December 2012 at the Radiotherapy Unit of King Abdulaziz University Hospital, Jeddah, Saudi Arabia, were retrospectively identified. The study was reviewed and approved by the institutional Research Ethics Committee.

All brachytherapy applications were performed under general anesthesia, without radiological guidance for uterine tandem insertion, by a radiation oncologist. Computed tomography images were then acquired using a Siemens Somatom Emotion CT-scanner (Siemens Medical Systems, Erlangen, Germany), with 2 mm slice intervals from the iliac crest to the distal end of the applicator.

The clinical-target-volume (CTV) and OARs volumes were defined on axial CT images for each brachytherapy fraction at the time of treatment planning, and retrospectively reviewed by one radiation oncologist, for the purpose of this study. The gross-target-volume (GTV) was delineated based on the CT information at the time of the brachytherapy and clinical findings. Isotropic margin (usually 1 cm) was added to generate the CTV. Primarily, the cervix and the lower uterine segment were included. If there was an involvement of the fornices or proximal vagina, these were also encompassed. Organ-at-risk volumes were the rectum and bladder. The outer rectal wall was contoured from the recto-sigmoid junction till 1 cm above the anal verge, and the outer bladder wall was contoured till the urethra.

Demographic and clinical data such as: patients' age, International Federation of Gynecology and Obstetrics (FIGO) stage, initial tumor volume and residual tumor volume after EBRT were collected.

Computed tomography-based treatment plans were reviewed for uterine perforation or near-perforation (sub-serosal insertion of tandem, i.e. within 5 mm from the uterine serosa), as presented in [Figure 1](#F0001){ref-type="fig"}. For each patient, the plans showing sub-optimal insertion of intra-uterine tandem were analyzed and compared to plans with optimal insertion for the same patient. The difference in dose coverage of CTV was evaluated by the doses delivered to 90% (D~90~) and 100% (D~100~) of CTV. The variation of the dose received by 1 cc (D~1cc~) and 2 cc (D~2cc~) of OARs was also determined and analyzed to assess any possible correlation with the position of the uterine tandem relative to the uterus. All CT-based brachytherapy plans were generated using Varian Brachyvision planning system, versions 8.0 and 10.0, for Varian HDR VariSource 200 and iX (Varian Medical Systems Inc., Palo Alto, CA, USA).

![Examples of uterine perforation (A) and sub-serosal insertion of intra-uterine tandem (B), in sagittal and coronal views](JCB-7-24546-g001){#F0001}

The correlation between incidence of uterine perforation and patients' variables was assessed using logistic regression analysis. The statistical analysis of dosimetry data was performed using the Student\'s *t*-test and a *p* value of \< 0.05 was considered significant.

Results {#S0003}
=======

A total of 231 brachytherapy plans for 82 patients were reviewed. We identified 34 (14.7%) treatment plans with sub-optimal insertion of intra-uterine tandem in 20 (24.4%) patients: 14 (6%) applications with uterine perforation and 20 (8.6%) applications with sub-serosal insertion of tandem. Four patients (4.8%) presented both uterine perforation and sub-serosal insertion. Patient clinical characteristics are summarized in [Table 1](#T0001){ref-type="table"}.

###### 

Patient characteristics (*n* = 82)

  Characteristics                 Optimal insertion (*n* = 62)   Sub-optimal insertion (*n* = 20)                 
  ------------------------------- ------------------------------ ---------------------------------- ------------- ------
  Brachytherapy fractions         197                            85.3                               34            14.7
  Age (years)                                                                                                     
   Range                          22-76                                                             38-79         
   Median                         52                                                                55.5          
  Stage                                                                                                           
   IB                             2                              3.2                                1             5
   IIA                            3                              4.8                                0             0
   IIB                            48                             77.4                               10            50
   IIIA                           2                              3.2                                0             0
   IIIB                           4                              6.5                                9             45
   IVA                            1                              1.6                                0             0
   Unknown                        2                              3.2                                0             0
  Initial tumor size (cc)                                                                                         
   Range                          1.1-510.1                                                         4.4-189.8     
   Mean ± SD                      74.7 ± 97.1                                                       63.4 ± 58.3   
   Unknown                        19                             30.6                               6             30
  Residual tumor size (cc)                                                                                        
   Range                          0.5-90.8                                                          0.5-20.7      
   Mean ± SD                      14.4 ± 25.8                                                       7.1 ± 8.7     
   CR                             16                             25.8                               4             20
   Unknown                        30                             48.4                               8             40
  Site of sub-optimal insertion                                                                                   
   Fundus uteri                                                                                     5             25
   Posterior uterine wall                                                                           12            60
   Anterior uterine wall                                                                            3             15

SD -- standard deviation, CR -- complete response

Applicators were not removed in all sub-optimal insertions; the tip of the tandem (which was outside of the uterine canal) was not loaded and the planned radiotherapy dose was delivered. Patients were stable and managed conservatively, with no reported major complications such as excessive bleeding, sepsis or other organ injury. Although it has been noticed a correlation between patient\'s age (median 55.5 years) and advanced disease stage (IIB and IIIB) and the incidence of a sub-optimal insertion of intra-uterine tandem, the logistic regression analysis showed that only the stage could be a predictor for a sub-optimal implant (*p* = 0.005) but not the age (*p* = 0.18). Due to limited data regarding the initial and residual tumor volume post EBRT, its relation to the incidence of sub-optimal implants could not be analyzed.

Among the 20 patients (34 plans) having sub-optimal implants, there were 6 patients (17 plans) in which all the brachytherapy plans revealed sub-optimal insertion of intra-uterine tandem, therefore they were excluded from the dosimetric analysis, as no individual reference plans were available for comparison. Dose distribution and dose-volume histograms (DVHs) analysis was performed for the remaining 14 patients (17 sub-optimal implant plans), and showed large variations when compared to the plans with optimal intra-uterine insertion. The percent differences in dose coverage of CTV (assessed by D~90~) and dose received by 1 cc and 2 cc of rectum and bladder are presented in [Table 2](#T0002){ref-type="table"}.

###### 

Dose comparison in 14 patients between plans for sub-optimal (sub-serosal and uterine perforation) and optimal insertion of intra-uterine tandem, reported as percentage dose difference

  Location   Constraints   Sub-serosal insertion of tandem   Uterine perforation                     
  ---------- ------------- --------------------------------- --------------------- ----------------- -------
  CTV        D~90~         --65.2 ± 82.8                     0.025                 --115.7 ± 134.9   0.042
             D~100~        --103.4 ± 170.4                   0.078                 --102.8 ± 132.3   0.13
  Rectum     D~1cc~        --12.2 ± 52.3                     0.46                  20.2 ± 32.7       0.065
             D~2cc~        --12.2 ± 48.2                     0.49                  21\. ± 30.6       0.051
  Bladder    D~1cc~        --16.3 ± 31.7                     0.061                 4.1 ± 36.7        0.23
             D~2cc~        --14.1 ± 29.6                     0.085                 2.1 ± 36.3        0.27

CTV -- clinical-target-volume, D~90~ -- the minimum dose to 90% of the CTV, D~100~ -- the minimum dose to 100% of the CTV, D~1cc~ -- minimum dose to the most exposed 1 cm^3^, D~2cc~ -- minimum dose to the most exposed 2 cm^3^

The percent difference of D~90~ between sub-optimal and optimal implant plans showed a significant decrease: from 0.74% to --319% (average: --115.7% ± 134.9%) for uterine perforation and from 12% to --223.8% (average: --65.2% ± 82.8%) for sub-serosal insertion of uterine tandem (*p* = 0.025), as shown in [Figure 2](#F0002){ref-type="fig"}.

![Percent differences between sub-optimal implant and optimal insertion of intra-uterine tandem in the same patient for 14 patients (17 plans), regarding D90 of CTV. The black markers show the sub-serosal insertion of tandem and the gray ones the uterine perforation](JCB-7-24546-g002){#F0002}

The variations of the dose received by the OARs rectum and bladder were further analyzed, in order to detect a possible correlation of the dose with the position of the uterine tandem (site of perforation) relative to the uterus. The results showed that the rectum dose, assessed by D~2cc~ increased up to 70.3% if the sub-serosal insertion of uterine tandem occurred in the posterior uterine wall, and up to 39.7% if in the uterine fundus. The bladder dose appeared not to be so sensitive to the uterine tandem position: the maximum variations of D~2cc~ were 37.4% in the posterior uterine wall and 43.8% in the uterine fundus. The percent differences between sub-optimal and optimal intra-uterine tandem insertion for D~2cc~ of rectum and bladder are presented in [Figure 3](#F0003){ref-type="fig"}.

![Percent differences between sub-optimal implant and optimal insertion of intra-uterine tandem in the same patient for 14 patients (17 plans), regarding D2cc of rectum (A) and D2cc of bladder (B). The black markers show the sub-serosal insertion of tandem and the gray ones the uterine perforation](JCB-7-24546-g003){#F0003}

Discussion {#S0004}
==========

Brachytherapy is an essential component of cervical cancer treatment. The technical quality of brachytherapy implant has been shown to significantly affect the clinical outcome of the treatment \[[@CIT0009]--[@CIT0011]\]. In a recent study, Viswanathan *et al*. showed that inappropriate placement of brachytherapy applicators led to significant risk of local recurrence (2.5 times) and lower DFS rate (2.28 times) \[[@CIT0011]\].

Few published reports addressed the uterine perforation during brachytherapy, using either low-dose-rate (LDR) or HDR \[[@CIT0007], [@CIT0012]--[@CIT0014]\]. In the case of LDR intracavitary brachytherapy, Barnes *et al*. presented an incidence of CT detected uterine perforation of 13.7%, although in 8.2% of insertions the physician was confident of correct tandem placement \[[@CIT0007]\]. An incidence of 2% was reported by Petereit *et al*., using ultrasound in only 6% of cases, therefore the true occurrence of uterine perforation was probably underestimated \[[@CIT0014]\]. Granai *et al*. employed post-operative B-mode ultrasound to evaluate final tandem position in 50 consecutive insertions in 28 patients. In 34%, the tandem was found to be sub-optimally positioned: in 24% it penetrated the myometrium, and in 10% completely perforated the uterus \[[@CIT0015]\]. In a recent study reporting one of the lowest incidence of uterine perforation in literature, Segedin *et al*. determined 3% incidence of uterine perforation among 428 image-guided brachytherapy applications \[[@CIT0016]\]. The authors emphasized the importance of using CT/MR imaging post insertion to accurately identify uterine perforation and used ultrasound guidance in 40% of subsequent applications after perforation.

Our study shows comparable data: 14.7% of the analyzed brachytherapy treatment plans presented sub-optimal insertion of intra-uterine tandem: 6% with uterine perforation and 8.6% with sub-serosal insertion of tandem. At our institution, uterine tandem insertion is a blind technique, performed without image guidance that would directly visualize pelvic structures, and depends on physician\'s clinical judgment and skills. This explains a higher incidence of perforation in our study, when compared to Segedin *et al*. (6% vs. 3%) \[[@CIT0016]\]. Prior to tandem insertion, it may be difficult to predict which patients are at risk of perforation. Risk factors that have been reported include age over 60 and anatomical distortion of the cervix (due to advanced disease, cervical stenosis, radiation fibrosis, or previous cone biopsy), which can make it difficult to localize the cervical os or subsequent dilation of the endocervical canal \[[@CIT0007], [@CIT0012], [@CIT0017]--[@CIT0019]\].

Barnes *et al*. demonstrated that significant predictors of uterine perforation are patient age greater than or equal to 60 (*p* = 0.0019) and tumor size (*p* = 0.0016) \[[@CIT0007]\]. Our data showed stage to be a predictor for a sub-optimal insertion (*p* = 0.005) but not the age (*p* = 0.18). Advanced disease may be associated with distortion of the cervix, difficulty to identify or localize the os, friability of cervical stroma, and uterine wall (if involved), which could increase the risk of a false track and perforation.

Nevertheless, post-insertion imaging is currently used to confirm correct uterine tandem placement, as well as to enable advanced brachytherapy planning \[[@CIT0020]--[@CIT0024]\]. Given the fixed angulation of commercially available uterine tandems, perforation risk is increased in marked ante-verted or retro-verted uteri \[[@CIT0025], [@CIT0026]\]. We found that 60% of the perforations occurred in the posterior uterine wall, 25% in the fundus, and 15% in the anterior wall, while Segedin *et al*. reported 70% in the posterior uterine wall, 15% in the fundus, and 15% in the anterior wall \[[@CIT0016]\]. In addition to injuring the pelvic organs, sub-optimal insertion of intra-uterine tandem can lead to inadequate radiation delivery and can subsequently alter the expected clinical outcome.

Our study showed that sub-optimal uterine tandem insertion can considerably affect the quality of the brachytherapy plans. The dose coverage of CTV, assessed by D~90~, showed a significant decrease, with an average of 115.7% ± 134.9% for uterine perforation, and 65.2% ± 82.8% for sub-serosal insertion of uterine tandem (*p* = 0.025). The doses received by rectum and bladder, and evaluated by D~2cc~ increased with an average of 21.0% ± 30.6% for rectum, and 2.1% ± 36.3% for bladder, in the case of uterine perforation. While the bladder dose appeared not to be sensitive to the position of the uterine tandem relative to the uterine cavity, the rectum dose markedly increased when the sub-optimal insertion of tandem occurred in the posterior uterine wall.

Several reports investigated the effect of applicator displacement on brachytherapy plan dosimetry, and emphasized the importance of image guidance and comprehensive quality control in the practice of brachytherapy \[[@CIT0027]--[@CIT0030]\]. However, published data on the effect of mal-placement of brachytherapy applicators on plan quality are scarce, hence a comparison with our data was not possible. Furthermore, the clinical significance of carrying out brachytherapy with a sub-optimally inserted intra-uterine tandem is not yet determined.

Pelvic magnetic resonance (MR) imaging after EBRT and before brachytherapy is a useful modality to assess the residual tumor and the orientation of uterus. For patients predicted to be at risk of perforation, ultrasound-guided insertion of applicators should be considered to minimize patient morbidity \[[@CIT0021]\]. Intracavitary brachytherapy procedures are gradually becoming image-guided. Various authors have used X-ray fluoroscopy, ultrasonography, CT scan, MRI, and laparoscopy for guiding brachytherapy procedures in gynecological malignancies. Methods such as CT and MR scans have practical limitations and are rarely used. Transrectal ultrasound (TRUS) can provide real time imagery of pelvic structures and movement of applicators, and thus potentially help in avoiding perforation and injury to OAR. It has many advantages in terms of easy availability, simple, and cost effective equipment, free from ionizing radiation \[[@CIT0031]\]. Even though ultrasound-guidance is known to reduce the risk of uterine perforation, it is not yet used routinely by many clinicians \[[@CIT0032]\].

The use of traditional X-ray simulations may make the planner unaware of the true position of the central tandem, which if loaded in the intra-abdominal location could risk the small intestine to be exposed to serious radiation dosages \[[@CIT0033]\]. Post-insertion imaging techniques such as ultrasound, CT or MR, have been shown to detect uterine perforation in up to 66% of cases when clinical assessment suggested proper tandem placement, and have been recommended by several authors \[[@CIT0019]--[@CIT0022], [@CIT0033], [@CIT0034]\]. Some authors have even suggested additional pelvic imaging following tandem insertion for all patients \[[@CIT0007], [@CIT0035]\]. Image-guided brachytherapy has a double advantage in that it not only allows the detection of inadequate placement of the applicators but also gives the opportunity of dose optimization during the planning process.

An obvious limitation of the present study is the small number of patients presenting uterine perforation. Statistical analysis of such a small sample size could not be valid if generalized at patient population level, and future studies with large sample sizes are recommended.

Conclusions {#S0005}
===========

We report relatively low incidence rates of uterine perforation and sub-serosal insertion of uterine tandem in CT-guided intracavitary HDR brachytherapy for cervix carcinoma, without image guidance during applicators insertion. The effects on CTV coverage and rectal dose were considerably detrimental. Based on our data, we advise image-guided tandem insertion, at least for challenging cases.
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